The London and Cambridge Life Sciences team advised Novo Holdings as lead investor in a $60 million Series C financing round into Exscientia, the world leading artificial intelligence (AI) drug discovery company. In addition to Novo Holdings, existing investors Evotec, Bristol Myers Squibb, and GT Healthcare Capital Partners (through certain LPs) participated in the round.
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation and is recognised as a leading international life science investor. Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies.
Exscientia is a global AI-driven drug discovery company, which recently continued to expand its portfolio into critical disease areas through signing multi-project partnerships with Bristol Myers Squibb, Bayer, Rallybio and GT Apeiron. In March this year, Exscientia announced a joint initiative to identify COVID-19 antiviral treatments with Diamond Light Source and Scripps Research.
The Goodwin team was led by Sophie McGrath, Adam Thatcher and Matthew Shelley.
For more information on the financing, please read the press release.